Stay updated on Daratumumab Post-Transplant in Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Daratumumab Post-Transplant in Multiple Myeloma Clinical Trial page.

Latest updates to the Daratumumab Post-Transplant in Multiple Myeloma Clinical Trial page
- Check6 days agoChange DetectedAdded a glossary display and updated QC metadata labels (e.g., Last Update Submitted that Met QC Criteria) along with a new revision note (v3.4.0), replacing prior wording (v3.3.4).SummaryDifference0.2%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe page's revision metadata was updated from v3.3.3 to v3.3.4, with no changes to study details, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check42 days agoChange DetectedAdded a Locations section listing California and Tennessee study sites; removed the separate California Locations and Tennessee Locations entries. Revision: v3.3.3.SummaryDifference0.3%

- Check56 days agoChange DetectedNew study record dates were added (e.g., 2025-12-05, 2025-12-03) and the primary completion date is listed as 2026-07-01; contemporaneously, earlier date entries (2025-08-26, 2025-08-22, 2025-11-17) were removed.SummaryDifference0.3%

- Check71 days agoChange DetectedRevision notes were updated to add v3.3.2 and remove v3.2.0, with no visible changes to the study content or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check78 days agoChange DetectedThe government funding/operating status notice at the top of the page has been removed. The study details, eligibility criteria, and related links remain unchanged.SummaryDifference0.4%

Stay in the know with updates to Daratumumab Post-Transplant in Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab Post-Transplant in Multiple Myeloma Clinical Trial page.